The TRIPS architecture is the first instantiation of an EDGE instruction set, a new, post-RISC class of instruction set architectures intended to match semiconductor technology evolution over the next decade, scaling to new levels of power efficiency and high performance.
This paper describes the
polymorphous
TRIPS architecture which can be configured for different granularities and types of parallelism. TRIPS contains mechanisms that enable the processing cores and the on-chip memory system to be configured and combined in different modes for instruction, data, or thread-level parallelism. To adapt to small and large-grain concurrency, the TRIPS architecture contains four out-of-order, 16-wide-issue Grid Processor cores, which can be partitioned when easily extractable fine-grained parallelism exists. This approach to polymorphism provides better performance across a wide range of application types than an approach in which many small processors are aggregated to run workloads with irregular parallelism. Our results show that high performance can be obtained in each of the three modes--ILP, TLP, and DLP-demonstrating the viability of the polymorphous coarse-grained approach for future microprocessors.
The pathophysiology of diabetes is multifactorial and no single etiology is at the forefront. The proposed mechanisms of erectile dysfunction (ED) in diabetic patients includes elevated advanced glycation end-products (AGEs) and increased levels of oxygen free radicals, impaired nitric oxide (NO) synthesis, increased endothelin B receptor binding sites and ultrastructural changes, upregulated RhoA/Rho-kinase pathway, NO-dependent selective nitrergic nerve degeneration and impaired cyclic guanosine monophosphate (cGMP)-dependent kinase-1 (PKG-1). The treatment of diabetic ED is multimodal. Treatment of the underlying hyperglycemia and comorbidities is of utmost importance to prevent or halt the progression of the disease. The peripherally acting oral phosphodiesterase type 5 (PDE5) inhibitors are the mainstay of oral medical treatment of ED in diabetics. Vacuum erection devices are an additional treatment as a non-invasive treatment option. Local administration of vasoactive medication via urethral suppository or intracorporal injection can be effective with minimal side-effects. Patients with irreversible damage of the erectile mechanism are candidates for penile implantation. Future strategies in the evolution of the treatment of ED are aimed at correcting or treating the underlying mechanisms of ED. With an appropriate vector, researchers have been able to transfect diabetic animals with agents such as neurotrophic factors and nitric oxide synthase (NOS). Further studies in gene therapy are needed to fully ascertain its safety and utility in humans.
This paper describes the polymorphous TRIPS architecture which can be configured for different granularities and types of parallelism. TRIPS contains mechanisms that enable the processing cores and the on-chip memory system to be configured and combined in different modes for instruction, data, or thread-level parallelism. To adapt to small and large-grain concurrency, the TRIPS architecture contains four out-of-order, 16-wide-issue Grid Processor cores, which can be partitioned when easily extractable fine-grained parallelism exists. This approach to polymorphism provides better performance across a wide range of application types than an approach in which many small processors are aggregated to run workloads with irregular parallelism. Our results show that high performance can be obtained in each of the three modes-ILP, TLP, and DLP-demonstrating the viability of the polymorphous coarse-grained approach for future microprocessors.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.